Last reviewed · How we verify
PF-05280586
PF-05280586 is a monoclonal antibody that blocks OX40, a costimulatory receptor on T cells, to enhance anti-tumor immune responses.
PF-05280586 is a monoclonal antibody that blocks OX40, a costimulatory receptor on T cells, to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (in combination with other immunotherapies).
At a glance
| Generic name | PF-05280586 |
|---|---|
| Sponsor | Pfizer |
| Drug class | OX40 agonist monoclonal antibody |
| Target | OX40 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
OX40 is an inducible T cell costimulatory molecule that enhances T cell proliferation, survival, and effector function. By agonizing OX40 on activated T cells, PF-05280586 amplifies tumor-specific T cell responses and promotes anti-tumor immunity. This approach aims to overcome immune suppression in the tumor microenvironment.
Approved indications
- Advanced or metastatic solid tumors (in combination with other immunotherapies)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Diarrhea
- Rash
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1, PHASE2)
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial (PHASE2)
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (PHASE2)
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (PHASE3)
- Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (PHASE1)
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-05280586 CI brief — competitive landscape report
- PF-05280586 updates RSS · CI watch RSS
- Pfizer portfolio CI